For the first time in history, a vaccine designed to treat lung cancer — not prevent infection, but hunt down and destroy tumor cells — is being tested in human patients. The trial, launched across 34 research sites in seven countries, marks a pivotal moment in the long effort to turn the immune system into a precision weapon against the world’s deadliest cancer.
At a glance
- mRNA lung cancer vaccine: BNT116, developed by BioNTech, uses messenger RNA technology — similar to COVID-19 vaccines — to present the immune system with tumor markers from non-small cell lung cancer, priming the body to attack cells expressing those markers.
- Clinical trial scale: The phase 1 trial is running at 34 sites across the U.K., U.S., Germany, Hungary, Poland, Spain, and Turkey, with approximately 130 patients enrolled from early-stage to recurrent disease.
- First patient dosed: Janusz Racz, a 67-year-old AI scientist from London, became the first person in the U.K. to receive the vaccine — six consecutive injections over 30 minutes at University College London Hospitals NHS Foundation Trust.
Why lung cancer makes this milestone matter
Lung cancer kills approximately 1.8 million people every year — more than any other cancer. Survival rates for advanced stages, where tumors have spread beyond the lungs, remain devastatingly low despite decades of research and treatment advances.
Non-small cell lung cancer accounts for the vast majority of those cases. Even patients who undergo surgery or radiation often face recurrence. That pattern — treat, remit, return — is precisely what this vaccine is designed to interrupt.
The goal of BNT116 is not just to shrink tumors but to give the immune system a lasting memory of what cancer cells look like, so it can recognize and destroy them before they establish again. Administered alongside immunotherapy, the jab is designed to reinforce a patient’s own defenses rather than replace them.
How the mRNA approach works
The mechanism draws directly on lessons learned from COVID-19 vaccine development. mRNA technology works by delivering genetic instructions that teach immune cells to recognize specific proteins found on the surface of cancer cells — called antigens. Once trained, those immune cells can identify and eliminate cells carrying those markers.
Crucially, healthy cells don’t carry the same markers. That selectivity is a major departure from chemotherapy, which attacks rapidly dividing cells broadly and causes significant collateral damage to healthy tissue.
“It’s simple to deliver, and you can select specific antigens in the cancer cell, and then you target them,” said Prof. Siow Ming Lee, a consultant medical oncologist at UCLH who is leading the U.K. arm of the trial. “This technology is the next big phase of cancer treatment.”
Racz received his first doses in a 30-minute session and will continue weekly injections for six weeks, followed by doses every three weeks for 54 weeks. Each injection contained different RNA strands targeting distinct tumor markers.
A scientist becomes a patient — and a participant
Racz’s decision to enroll was shaped by his own professional identity. Diagnosed with lung cancer in May 2024 C.E., he began chemotherapy and radiotherapy before joining the BNT116 trial. As a researcher, he understood the stakes on both sides of the equation.
“I am a scientist too, and I understand that the progress of science — especially in medicine — lies in people agreeing to be involved in such investigations,” he said. He described hoping to provide “proof of concept” for a methodology that, once validated, could be deployed globally.
His personal goal, once treatment ends: completing the London Marathon.
The road ahead — and the limits of phase 1
It’s important to hold this moment with appropriate perspective. Phase 1 trials are designed primarily to assess safety, not efficacy. The 130 patients enrolled in BNT116’s first human study will help researchers understand how the vaccine behaves in real immune systems, what side effects emerge, and what dosing looks like — not yet whether it reliably extends survival.
The path from here to standard-of-care treatment, if the science holds, runs through phase 2 and phase 3 trials, regulatory review, and manufacturing scale-up — a timeline measured in years, not months. Many promising cancer therapies have stumbled in later-stage trials after encouraging early results.
Still, the launch itself is significant. Prof. Lee, who has worked in lung cancer research for 40 years, noted that when he began his career in the 1990s, few believed chemotherapy could work against the disease at all. Today, roughly 20–30% of patients with stage 4 lung cancer survive long-term on immunotherapy alone — a number that was unthinkable a generation ago. The ambition now is to push that figure higher.
“We hope adding this additional treatment will stop the cancer coming back,” Lee said. “So hopefully this mRNA vaccine, on top of immunotherapy, might provide the extra boost.”
A broader shift in cancer treatment
The BNT116 trial is part of a wider movement toward personalized, mRNA-based cancer immunotherapy. BioNTech, the German biotechnology company that co-developed the Pfizer–BioNTech COVID-19 vaccine, has been investing heavily in applying the same platform to oncology. Moderna and other companies are pursuing parallel programs for melanoma, pancreatic cancer, and other tumor types.
The U.K.’s National Institute for Health and Care Research has been central to fast-tracking patient enrollment into these trials. A Cancer Vaccine Launch Pad program — announced earlier in 2024 C.E. — was designed to match eligible patients to relevant trials more rapidly than traditional recruitment allows, potentially cutting years off timelines for future phases.
The ambition, as Prof. Lee put it simply: “We hope it becomes standard of care worldwide and saves lots of lung cancer patients.”
That outcome is not guaranteed. But the fact that a vaccine targeting the world’s deadliest cancer is now being tested in human beings — using a platform refined through one of the most successful public health interventions in modern history — is a genuine milestone worth marking. The phase 1 results, expected in the coming years, will determine whether this moment becomes a turning point.
Read more
For more on this story, see: The Guardian
For more from Good News for Humankind, see:
- U.K. cancer death rates fall to their lowest level on record
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
